Validation of a New Clinical-Genetic Recursive Partitioning Analysis of High-Grade Glioma Using RTOG 0525, 0513 and 0131
Despite advances in our understanding/treatment of patients with high grade glioma, the current model for prognostication is based on 40-year-old data. We previously generated a new model incorporating clinical and genetic factors utilizing data from patients treated from 2004-2017. Here we sought t...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 111; no. 3; p. e601 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.11.2021
|
Online Access | Get full text |
ISSN | 0360-3016 1879-355X |
DOI | 10.1016/j.ijrobp.2021.07.1605 |
Cover
Abstract | Despite advances in our understanding/treatment of patients with high grade glioma, the current model for prognostication is based on 40-year-old data. We previously generated a new model incorporating clinical and genetic factors utilizing data from patients treated from 2004-2017. Here we sought to validate our prognostic model within data from prospective trials and compare its accuracy against the original RTOG-RPA.
Data from RTOG 0525, RTOG 0513 and RTOG BR-0131 was requested through an NRG Ancillary Project application. Subjects were categorized by both RTOG RPA survival class and our new-RPA survival class. We generated Kaplan-Meier survival curves for classes from each model. To compare the accuracy and heterogeneity of each model, we calculated the mean prediction errors and interquartile ranges (IQR) of overall survival (OS). We then compared the two models for their predictive ability and homogeneity within each survival class.
960 patients were included in our validation dataset. Using the validation dataset, Kaplan-Meier survival curves for each terminal class were plotted. Log rank tests demonstrated no significant differences between the predicted and observed survival curves of the new RPA for Class 1 (P = 0.39), Class 2 (P = 0.59), Class 4 (P = 0.75), Class 5 (P = 0.18), Class 6 (P = 0.50), and Class 3/5 (P = 0.12). Mean prediction error of median survival was 4.5 months vs 1.9 months for the RTOG- and new-RPA, respectively. Mean Kaplan-Meier OS IQR was 38.1 months and 17.8 months for the RTOG- and new-RPA, respectively.
We demonstrated that both the RTOG-RPA and our new-RPA classes maintain their relative prognostic significance. Although both models generate 6 distinct survival classes, in this partial validation our updated model more accurately predicts median survival for each class with significantly greater class homogeneity. Additionally, our proposed model utilizes exclusively objective measures decreasing the risk of inter-observer classification variability.
P. Sutera: None. J.C. Flickinger: None. H. Wang: None. D.E. Heron: None. |
---|---|
AbstractList | Despite advances in our understanding/treatment of patients with high grade glioma, the current model for prognostication is based on 40-year-old data. We previously generated a new model incorporating clinical and genetic factors utilizing data from patients treated from 2004-2017. Here we sought to validate our prognostic model within data from prospective trials and compare its accuracy against the original RTOG-RPA.
Data from RTOG 0525, RTOG 0513 and RTOG BR-0131 was requested through an NRG Ancillary Project application. Subjects were categorized by both RTOG RPA survival class and our new-RPA survival class. We generated Kaplan-Meier survival curves for classes from each model. To compare the accuracy and heterogeneity of each model, we calculated the mean prediction errors and interquartile ranges (IQR) of overall survival (OS). We then compared the two models for their predictive ability and homogeneity within each survival class.
960 patients were included in our validation dataset. Using the validation dataset, Kaplan-Meier survival curves for each terminal class were plotted. Log rank tests demonstrated no significant differences between the predicted and observed survival curves of the new RPA for Class 1 (P = 0.39), Class 2 (P = 0.59), Class 4 (P = 0.75), Class 5 (P = 0.18), Class 6 (P = 0.50), and Class 3/5 (P = 0.12). Mean prediction error of median survival was 4.5 months vs 1.9 months for the RTOG- and new-RPA, respectively. Mean Kaplan-Meier OS IQR was 38.1 months and 17.8 months for the RTOG- and new-RPA, respectively.
We demonstrated that both the RTOG-RPA and our new-RPA classes maintain their relative prognostic significance. Although both models generate 6 distinct survival classes, in this partial validation our updated model more accurately predicts median survival for each class with significantly greater class homogeneity. Additionally, our proposed model utilizes exclusively objective measures decreasing the risk of inter-observer classification variability.
P. Sutera: None. J.C. Flickinger: None. H. Wang: None. D.E. Heron: None. |
Author | Wang, H. Sutera, P. Heron, D.E. Flickinger Sr, J.C. |
Author_xml | – sequence: 1 givenname: P. surname: Sutera fullname: Sutera, P. organization: University of Pittsburgh School of Medicine, Pittsburgh, PA – sequence: 2 givenname: J.C. surname: Flickinger Sr fullname: Flickinger Sr, J.C. organization: Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA – sequence: 3 givenname: H. surname: Wang fullname: Wang, H. organization: University of Pittsburgh, Pittsburgh, PA – sequence: 4 givenname: D.E. surname: Heron fullname: Heron, D.E. organization: Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA |
BookMark | eNqNkMFqGzEQhkVJoU7aRyjoAbrbGclaeQ-lBNNsAqEpISm9CVmaTcfdaIPkuPHbx4tzyqW9zH_5v5_hOxZHaUwkxEeEGgGbz-ua13lcPdQKFNZga2zAvBEzXNi20sb8OhIz0A1Uet9-J45LWQMAop3PxNNPP3D0Gx6THHvp5Xf6K5cDJw5-qDpKtOEgryk85sJbkj983vDU5nQnT5MfdoXLRJ7z3e-qyz6S7AYe7728LVPn-uaqk2CU-bS_qKVPUQJqfC_e9n4o9OElT8Tt2beb5Xl1edVdLE8vq6CsNpVGjGisRqNiUN4aH6NpVB_nul8tFr5pqIWIyrQmgm3BztsIDan5QnvVrFb6RJjDbshjKZl695D53uedQ3CTPrd2B31u0ufAuknfnvt64Gj_3JYpuxKYUqDImcLGxZH_ufDl1UJ48fqHdv_BPwOVWI5r |
ContentType | Journal Article |
Copyright | 2021 |
Copyright_xml | – notice: 2021 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.ijrobp.2021.07.1605 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
EndPage | e601 |
ExternalDocumentID | 10_1016_j_ijrobp_2021_07_1605 S0360301621024755 |
GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 7-5 AAEDT AAEDW AALRI AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ADBBV AENEX AEVXI AFRHN AFTJW AGCQF AHHHB AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY DU5 EBS EFKBS F5P FDB GBLVA HED HMO IHE J1W KOM LX3 M41 MO0 O9- OC~ OO- RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ~S- AAIAV AFCTW AGZHU ALXNB EFJIC ZA5 .55 .GJ 29J 5VS AAQFI AAQQT AAQXK AAYWO AAYXX ABEFU ABWVN ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN AEUPX AFFNX AFJKZ AFPUW AGQPQ AGRDE AIGII AKBMS AKYEP ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB FIRID G-2 HMK HVGLF HX~ HZ~ NQ- R2- SAE SEW UDS X7M XPP ZGI |
ID | FETCH-LOGICAL-c2735-311d1573152dc2a75add562fd43fb88a66e90d12595d0790749d06e2483a26bb3 |
ISSN | 0360-3016 |
IngestDate | Wed Oct 01 01:55:19 EDT 2025 Fri Feb 23 02:40:35 EST 2024 Tue Aug 26 16:33:49 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2735-311d1573152dc2a75add562fd43fb88a66e90d12595d0790749d06e2483a26bb3 |
OpenAccessLink | https://doi.org/10.1016/j.ijrobp.2021.07.1605 |
ParticipantIDs | crossref_primary_10_1016_j_ijrobp_2021_07_1605 elsevier_sciencedirect_doi_10_1016_j_ijrobp_2021_07_1605 elsevier_clinicalkey_doi_10_1016_j_ijrobp_2021_07_1605 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-11-01 2021-11-00 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationYear | 2021 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0001174 |
Score | 2.3741004 |
Snippet | Despite advances in our understanding/treatment of patients with high grade glioma, the current model for prognostication is based on 40-year-old data. We... |
SourceID | crossref elsevier |
SourceType | Index Database Publisher |
StartPage | e601 |
Title | Validation of a New Clinical-Genetic Recursive Partitioning Analysis of High-Grade Glioma Using RTOG 0525, 0513 and 0131 |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0360301621024755 https://dx.doi.org/10.1016/j.ijrobp.2021.07.1605 |
Volume | 111 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-355X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001174 issn: 0360-3016 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-355X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001174 issn: 0360-3016 databaseCode: AKRWK dateStart: 19761001 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZKJyFe0LiJcZMfeBsJcZw46ePUjVWbBmjr2N4iXxKpHbQo6hDih-337Zw4ccyoGEOq0sqRLTfni8-Xk-8cE_I2UpmOcxMHI-DLQaJZHkhYE4PEGA2fijOFyclHH8XkNDk4T88HgytPtXS5UqH-tTav5H-sCm1gV8ySvYNl3aDQAL_BvnAEC8Pxn2z8BUi0cZxPNmLFttDn1wALSq8ambzGiMCPEthibUsTNaEQrxoJij2C_VoaVF_Mlt_ktlUSHE8_7W9HzdZFY_hmvHnVgLVzfE77e1DRK0VRY90DO7uFdlkxqk-QsWEVx-pPcHuJhsx-DntczfSFLZZ40oDrIBy7k2dtsHviWiZlbWUEu-Fe6Ec0Ytam9vULHxfgGyKbg-lWacY8OHJvzS2F7fyHM7BxiXk4m9dLhbVJYxbaeFrae7_ujf8Np-ikip0Kbl7YYQocpoiyAoe5RzbiTIh4SDZ2Do_PDh0HYG397-6f9Llj79fOZz0r8pjOdJM8bB9R6I7F2yMyKBePyf2jVoTxhPzsYUeXFZUUYEdvwo462FEfdrSDHfbsYUct7GgDO4qwowi7dxRBRwF0FEH3lJx-2JuOJ0G7gUeggRWjwoIZlmYcOKLRscxScKbAtyuT8ErluRSiHEUGKPYoNVGGYZqRiUQZJzmXsVCKPyPDxXJRPidUChlVGp4mjORJLnKVpqVKRWbSSnGZ6y0Sdhew-G7rtBR_Nd0WEd1lLrokZHCbBYDnto6569iyVMs-b-_64q6TfEke9DfIKzJc1ZflayDBK_WmRdw1eMSs3A |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation+of+a+New+Clinical-Genetic+Recursive+Partitioning+Analysis+of+High-Grade+Glioma+Using+RTOG+0525%2C+0513+and+0131&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Sutera%2C+P.&rft.au=Flickinger+Sr%2C+J.C.&rft.au=Wang%2C+H.&rft.au=Heron%2C+D.E.&rft.date=2021-11-01&rft.issn=0360-3016&rft.volume=111&rft.issue=3&rft.spage=e601&rft_id=info:doi/10.1016%2Fj.ijrobp.2021.07.1605&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ijrobp_2021_07_1605 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0360-3016&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0360-3016&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0360-3016&client=summon |